A comprehensive review outlines the three main barriers to oral peptide delivery — acid degradation, enzymatic breakdown, and poor membrane permeability — and describes current strategies including absorption enhancers, structural modifications, and nanoformulations.
3 major barriers to oral deliveryStomach acid, digestive enzymes, and poor intestinal membrane permeability collectively prevent most peptide drugs from being effective when taken as pills
What the researchers found
The review identifies three primary barriers to oral peptide/protein delivery:
1. Acid degradation in the stomach (pH 1-2)
2. Enzymatic degradation by proteases throughout the GI tract
3. Poor cellular membrane permeability at the intestinal absorption site, plus first-pass hepatic metabolism
Current strategies to overcome these barriers include:
- Absorption enhancers and carriers to improve gut permeability
- Structural modifications (cyclization, D-amino acid substitution, PEGylation) to improve stability
- Advanced formulation technologies (nanoparticles, liposomes, microspheres)
- Enzyme inhibitors to protect against proteolytic degradation
- Enteric coatings to bypass stomach acid
Why it matters
Billions of people worldwide could benefit from peptide drugs for diabetes, obesity, osteoporosis, and other chronic conditions, but injections limit adoption. Oral delivery would dramatically improve patient compliance, reduce healthcare costs, and expand access to these therapies. The success of oral semaglutide demonstrates that this barrier can be overcome, motivating further research.
The numbers in context
3 barriers: acid, enzymes, permeability; strategies: enhancers, modifications, nanoparticles, liposomes, advanced technologies
How the study worked
This is a narrative review summarizing the current state of knowledge on oral peptide and protein drug delivery. It covers physicochemical factors affecting bioavailability, barriers in the GI tract, and technological approaches to improving oral absorption of peptide therapeutics.
Who was studied
Review article (no study population)
What this study cannot tell us
As a review article from 2021, it does not capture the most recent developments in oral peptide delivery. The field is evolving rapidly, and some approaches described may have been superseded. Many of the technologies reviewed are still in early development stages with limited clinical validation. The review provides a broad overview rather than a detailed comparison of approach effectiveness.
How to read the evidence
This is a narrative review article summarizing existing research on oral peptide delivery challenges and solutions. It synthesizes published data but does not present original experimental results.
When this study was published
Published in 2021, this review captures the state of oral peptide delivery technology shortly after the approval of oral semaglutide. The field has continued to advance since publication.
The bigger picture
The oral peptide delivery challenge is one of the most important problems in pharmaceutical science. Its solution could transform the treatment of chronic diseases that currently require regular injections. The approval of oral semaglutide (Rybelsus) in 2019 was a landmark achievement, but it requires specific dosing conditions (fasting, limited water). Next-generation approaches aim to make oral peptide delivery as simple as taking any other pill.
Questions still open
- Which oral delivery strategy is most likely to succeed for a wide range of peptide drugs beyond semaglutide?
- Can nanoparticle-based approaches achieve sufficient bioavailability to compete with injectable peptide formulations?
- Will advances in oral peptide delivery eventually make injections obsolete for most peptide therapeutics?
Common questions
Why can't most peptide drugs be swallowed as pills?
Are there any oral peptide drugs available today?
Read the original research
Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability.
Drug development research, 82(7), 927-944
Citation
Verma, Saurabh; Goand, Umesh K; Husain, Athar; Katekar, Roshan A; Garg, Richa; Gayen, Jiaur R. (2021). Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability.. Drug development research, 82(7), 927-944. https://doi.org/10.1002/ddr.21832